首页> 美国卫生研究院文献>Journal of Clinical Microbiology >The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
【2h】

The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening

机译:Aptima HPV分析符合国际宫颈乳头瘤病毒检测要求的国际临床指南的跨部门标准

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Aptima HPV assay (Hologic Gen-Probe, San Diego, CA) is an FDA-approved assay for detecting human papillomavirus (HPV) E6/E7 mRNA from 14 high-risk HPV types. This study evaluated the clinical performance of the Aptima HPV assay for cervical intraepithelial neoplasia of grade 2 or worse (CIN2+), relative to the high-risk HPV GP5+/GP6+ PCR, in a cross-sectional clinical equivalence analysis using the noninferiority score test with cervical samples from population-based screening, i.e., 69 cervical scraping samples from women with CIN2+ and 843 from women without evidence of CIN2+. In addition, intralaboratory reproducibility over time and interlaboratory agreement of the Aptima HPV assay results were assessed with another set of 548 cervical samples. The Aptima HPV assay showed a clinical sensitivity for CIN2+ of 94.2% (95% confidence interval [CI], 85.5 to 97.8%) and a clinical specificity for CIN2+ of 94.5% (95% CI, 92.8 to 95.9%); by comparison, these figures were 97.1% (95% CI, 89.1 to 99.3%) (67/69 samples) and 93.6% (95% CI, 91.7 to 95.0%) (785/839 samples), respectively, for GP5+/GP6+ PCR. The clinical sensitivity and specificity of the Aptima HPV assay were noninferior to those of GP5+/GP6+ PCR (P = 0.039 and 0.00016, respectively). In addition, high reproducibility of the Aptima HPV assay, as reflected by the intralaboratory reproducibility over time of 96.0% (95% CI, 94.4 to 97.3%) (526/548 samples; kappa = 0.89) and interlaboratory agreement of 96.7% (95% CI, 95.4 to 98.1%) (531/548 samples; kappa = 0.91), was found. Altogether, these data show that the Aptima HPV assay meets the cross-sectional clinical and reproducibility criteria of the international guidelines for HPV test requirements for cervical screening. Longitudinal data are needed to ensure that the long-term negative predictive value of this mRNA assay is similar to those of validated HPV DNA tests.
机译:Aptima HPV检测(Hologic Gen-Probe,圣地亚哥,加利福尼亚州)是FDA批准的检测14种高危HPV类型的人乳头瘤病毒(HPV)E6 / E7 mRNA的检测方法。这项研究在横断面临床等效性分析中使用非劣效性评分测试与相对高危型HPV GP5 + / GP6 + PCR相比,评估了Aptima HPV检测法对2级或更严重的宫颈上皮内瘤变(CIN2 +)的临床表现。基于人群筛查的宫颈样本,即来自CIN2 +的女性的69例宫颈刮取样本和没有CIN2 +的女性的843例宫颈刮取样本。此外,还使用另一套548份宫颈样品评估了实验室内随时间推移的可重复性和实验室间Aptima HPV检测结果的一致性。 Aptima HPV检测显示CIN2 +的临床敏感性为94.2%(95%置信区间[CI]为85.5至97.8%),CIN2 +的临床特异性为94.5%(95%CI为92.8至95.9%)。相比之下,GP5 + / GP6 +的这些数字分别为97.1%(95%CI,89.1至99.3%)(67/69个样本)和93.6%(95%CI,91.7至95.0%)(785/839个样本)。 PCR。 Aptima HPV检测的临床敏感性和特异性不亚于GP5 + / GP6 + PCR的敏感性(分别为P = 0.039和0.00016)。此外,Aptima HPV测定法具有很高的重现性,反映出实验室内随时间推移的重现性为96.0%(95%CI,94.4至97.3%)(526/548个样品; kappa = 0.89)和实验室间一致性为96.7%(95)发现CI的百分比为95.4%至98.1%(531/548个样品; k = 0.91)。总而言之,这些数据表明,Aptima HPV检测符合宫颈筛查HPV检测要求的国际准则的横断面临床和可重复性标准。需要纵向数据以确保此mRNA检测的长期阴性预测值与经过验证的HPV DNA检测的相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号